Recent 8-K filings for RMTI

• May 8, 2026, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Rockwell Medical receives Nasdaq delisting notice for bid price below $1.00

  Notice issued May 8, 2026 for failing to meet $1.00 minimum bid price over 30 consecutive business days.

• May 7, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Rockwell Medical Q1 net sales $17.3M (-8% YoY); guides FY26 gross margin 18-22%

  Net sales $17.3M, down 8% from $18.9M; net loss $1.6M vs $1.5M in prior year.

• May 7, 2026, 7:59 PM ET other materiality 0.15 neutral item 7.01item 9.01

  Rockwell Medical makes corporate presentation available; no specifics extractable from filing text

  Rockwell Medical made an updated corporate presentation available on May 7, 2026.

• March 26, 2026, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Rockwell Medical Q4 2025 net sales $18.3M, gross margin 21% (up from 15%), full-year Adj. EBITDA $0.3M

  Q4 2025 net sales $18.3M (vs $24.7M Q4 2024); full-year net sales $69.3M (vs $101.5M) driven by reduced customer purchase volumes.

• March 26, 2026, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Rockwell Medical files updated corporate presentation; no material new information

  Corporate presentation dated March 26, 2026 made available under Item 7.01.

• January 20, 2026, 6:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Rockwell Medical prelim Q4 sales ~$18.6M; cash flow positive $2.3M

  Preliminary Q4 2025 net sales ~$18.6M; full-year 2025 ~$69.5M (audit pending).

• January 5, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01

  Rockwell Medical extends DaVita supply agreement to Dec 2026 with price hike

  Second Amendment extends Products Purchase Agreement through Dec 31, 2026.

• November 18, 2025, 6:59 PM ET leadership materiality 0.25 neutral item 5.02

  Rockwell Medical director resigns; Joseph H. Dawson appointed to board

  Director Andrea Heslin Smiley resigned Nov 17, 2025; resignation not due to disagreement.

• November 12, 2025, 6:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Rockwell Medical Q3 net sales fall 44% to $15.9M; net loss of $1.8M vs profit year ago

  Net sales $15.9M, down 44% YoY due to largest customer transitioning to another supplier.

• November 12, 2025, 6:59 PM ET other material materiality 0.30 neutral item 7.01item 9.01

  Rockwell Medical posts updated corporate presentation; no specific financial data disclosed

  Company made available an updated corporate presentation on November 12, 2025.

• September 29, 2025, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 9.01

  Rockwell Medical appoints Heather Hunter as SVP & COO effective Sept 23, 2025

  Heather Hunter appointed SVP & COO effective Sept 23, 2025; previously SVP & Chief Corporate Affairs Officer since Aug 2022.

• August 14, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Rockwell Medical Q2 2025 revenue drops 38% to $16.1M, net loss of $1.5M

  Net sales $16.1M, down 38% YoY, driven by loss of largest customer; gross margin 16% in line with guidance.

• May 20, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Rockwell Medical shareholders elect directors, approve advisory say-on-pay and 5M share increase

  Class I directors John G. Cooper and Allen Nissenson, MD re-elected with 14.3M and 14.4M votes for, respectively.

• May 12, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Rockwell Medical Q1 net sales $18.9M (-17% YoY); net loss improves to $1.5M

  Net sales fell 17% to $18.9M, driven by largest customer transitioning to another supplier.

• May 12, 2025, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Rockwell Medical posts updated corporate presentation; no material new details disclosed

  Updated investor presentation made available on May 12, 2025 under Item 7.01.

• March 20, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Rockwell Medical Reports Record Net Sales and First Full-Year Adjusted EBITDA Profitability in 2024

  Record net sales of $101.5M in 2024, a 21% increase over 2023.

• March 20, 2025, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Rockwell Medical furnishes updated corporate presentation; no specific new details provided

  Filed Item 7.01 Regulation FD disclosure with corporate presentation dated March 20, 2025.

• December 12, 2024, 6:59 PM ET leadership materiality 0.30 neutral item 5.02item 9.01

  Rockwell Medical appoints Jesse Neri as CFO effective December 10, 2024

  Jesse Neri, previously SVP Finance since Oct 2023, becomes CFO and Principal Financial Officer.

• November 13, 2024, 6:59 PM ET other material materiality 0.35 neutral item 8.01item 9.01

  Rockwell Medical files prospectus supplement for up to $25M ATM offering

  Filed new S-3 shelf registration on Oct 8, effective Oct 21, replacing expiring prior shelf.

• November 12, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Rockwell Medical Q3 2024 net income $1.7M, raises guidance; largest customer revenue expected to decline $31-38M in 2025

  Net product sales $28.3M (+31% YoY); gross profit $6.2M (+183%); gross margin 22% vs 9%.

• November 12, 2024, 6:59 PM ET other materiality 0.20 neutral item 7.01item 9.01

  Rockwell Medical provides updated corporate presentation; no specific financial data disclosed

  Company furnished an updated corporate presentation as Exhibit 99.1 to Form 8-K on November 12, 2024.

• August 8, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Rockwell Medical Q2 net sales $25.8M (+43% YoY), net income $0.3M, raises FY 2024 guidance

  Net sales $25.8M (+43% YoY); gross profit $4.6M (+341%); gross margin expanded to 18% from 6%.

• August 8, 2024, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Rockwell Medical issues updated corporate presentation; no material new details disclosed

  Presentation made available on August 8, 2024 under Item 7.01 Regulation FD.

• July 15, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 7.01item 9.01

  Rockwell Medical amends asset purchase deal with Evoqua; affirms 2024 gross margin guidance of 14-16%

  Amendment reduces First Deferred Payment by $322,260 to $2,177,740, payable in four quarterly installments through April 2025.

• May 23, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Rockwell Medical shareholders elect directors, approve compensation, ratify auditor at 2024 annual meeting

  Robert Radie and Mark Strobeck elected Class III directors with ~11.5M votes each; broker non-votes ~8.1M.

• May 14, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Rockwell Medical Q1 record sales $22.7M (+15% YoY); raises 2024 guidance across all metrics

  Q1 net sales $22.7M (record), up 15% YoY; ex-deferred revenue, up 25%. Gross profit $3.1M (+18% YoY).

• May 14, 2024, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Rockwell Medical furnishes updated corporate presentation; details not disclosed in filing text

  Item 7.01 disclosure: company made available an updated corporate presentation on May 14, 2024.

• March 21, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Rockwell Medical posts record 2023 net sales of $83.6M; achieves first-ever adjusted EBITDA profit in Q4

  Q4 2023 net sales $22.1M (+14% YoY); Q4 adjusted EBITDA $0.5M vs ($0.6M) in Q4 2022, first positive quarter in company history.

• March 21, 2024, 7:59 PM ET other material materiality 0.15 neutral item 7.01item 9.01

  Rockwell Medical furnishes updated corporate presentation on March 21, 2024

  Presentation filed as Exhibit 99.1; specific content (strategy, financials, pipeline) not reproduced in 8-K text.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.50 · Most common event earnings

7 positive 4 negative 18 neutral

source · RMTI on sec.gov